3Franssen CFM, Stegen CA, Kallenberg CGM, et al. Antiproteinase 3 and antimyeloperoxidase associated vasculitis[J]. Kid Intern, 2000,57: 2195-2206.
4Hochberb MC. Updaling the American College of Rheumatology revised criteria for the classification of systemic lupusrythematosus [J]. Arthritis Rheum, 1997,40(6): 1725.
5Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients [J]. Arthritis- Rheum, 1992, 35(6): 630-640.
6Molnar K, Kovacs L, Kiss M, et al. Anti-neutrophil cytoplasmic anti- bodies in patients with systemic lupus erythematosus [J]. Clin Exp Dermatol, 2002,27( 1 ) :56-61.
7Schnable A, Csemo KE, Isenberg DA, et al. Antineutrophil cytoplas- mic antibodies in systemic lupus erythematosus; Prevalence's peci- ficifies, and clinical significance [J]. Arthritis Rheum, 1995,38: 633-637.
8SONG YH. KIM TH,LEE IH,et al. Wenger granulomatosis presenting as mediastinal soft tissue mass invading the tracheal wall.Clin-Rheumatol, 2000,19 (6):495-498.
9Activation of Neutrophils Eosinophils, and Lymphoeytes In the Lower Respiratory Tract In Wegenera Granulomatosis. Am J Respir Crit Care Med Vol,2000,161(1) :399-405.
